Alligator Bioscience AB
STO:ATORX

Watchlist Manager
Alligator Bioscience AB Logo
Alligator Bioscience AB
STO:ATORX
Watchlist
Price: 5.63 SEK 12.75%
Market Cap: 173.9m SEK

Net Margin
Alligator Bioscience AB

-353.4%
Current
-575%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-353.4%
=
Net Income
-179.5m
/
Revenue
50.8m

Net Margin Across Competitors

Alligator Bioscience AB
Glance View

Market Cap
173.9m SEK
Industry
Biotechnology

Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody-based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 46 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The firm operates domestically.

ATORX Intrinsic Value
14.5 SEK
Undervaluation 61%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-353.4%
=
Net Income
-179.5m
/
Revenue
50.8m
What is the Net Margin of Alligator Bioscience AB?

Based on Alligator Bioscience AB's most recent financial statements, the company has Net Margin of -353.4%.

Back to Top